Messenger RNA Quality Control in Aging and Age-Related Disease

Key Takeaways

• mRNA surveillance declines with age
• NMD, NSD, NGD linked to neurodegeneration
• Stalled ribosomes accumulate in aged cells
• Enhancing surveillance may extend longevity
• Model organisms reveal surveillance’s role in aging

Summary

Cellular health depends on rigorous quality control of messenger RNA, yet these surveillance pathways weaken with age. Research in C. elegans and yeast shows that impaired nonsense‑mediated decay, nonstop decay, and no‑go decay lead to ribosome stalling, protein aggregation, and accelerated senescence. The review highlights how failures in mRNA quality control contribute to neurodegenerative disease and cancer, and suggests that boosting these mechanisms could delay aging. Understanding these links opens new therapeutic avenues for age‑related disorders.

Pulse Analysis

Messenger RNA (mRNA) quality control is a cornerstone of cellular homeostasis, ensuring that only correctly processed transcripts reach the ribosome for protein synthesis. Eukaryotic cells employ several surveillance pathways—nonsense‑mediated decay (NMD), nonstop decay (NSD), and no‑go decay (NGD)—to recognize and eliminate transcripts bearing premature stop codons, missing stop signals, or structural impediments that cause ribosome stalling. These mechanisms intersect with codon‑optimality‑mediated decay and ribosome‑associated quality control (RQC), forming a multilayered network that prevents the accumulation of toxic, misfolded proteins. As the first line of defense against transcriptional noise, mRNA QC directly influences proteostasis and genomic stability.

Recent studies in Caenorhabditis elegans and Saccharomyces cerevisiae have demonstrated that age‑related decline in these surveillance systems correlates with increased ribosome collisions and stalled translation complexes. In aged worms, reduced NMD activity accelerates the buildup of aberrant transcripts, shortening lifespan, while yeast mutants deficient in NSD or NGD exhibit premature senescence and heightened sensitivity to oxidative stress. The accumulation of stalled ribosomes not only disrupts translation efficiency but also triggers downstream stress responses that exacerbate cellular senescence, linking mRNA QC failure to neurodegeneration and cancer phenotypes observed in older organisms.

Because mRNA surveillance sits at the nexus of transcription, translation, and protein quality control, it presents an attractive target for therapeutic intervention. Small‑molecule enhancers of NMD or modulators of RQC could restore clearance of faulty transcripts, thereby improving proteome integrity and extending healthspan. Pharmaceutical pipelines are beginning to explore RNA‑focused drug discovery, and integrating mRNA QC modulation may complement existing anti‑aging strategies such as senolytics and proteostasis regulators. Continued investment in high‑throughput screens and biomarker development will be essential to translate these mechanistic insights into clinically viable treatments for age‑related diseases.